VISCHER advised Numab in its global alliance with Kaken Pharmaceutical

Numab Therapeutics signed a global development agreement and regional license agreement with Kaken Pharmaceutical for Numab’s novel multi-specific anti-inflammatory drug candidate NM26-2198, which blocks three key pathways in the pathophysiology of atopic dermatitis. The alliance is based on a cooperation and option agreement concluded in 2017. Under the expanded agreement, Kaken will receive commercial rights to NM26-2198 in Japan, China, South Korea, Taiwan, Singapore and Hong Kong, while Numab will retain commercial rights for the US, Europe and the rest of the world. The parties will jointly develop NM26-2198, with Kaken bearing most of the global development costs up to clinical proof of concept.

VISCHER advised Numab on this alliance. The team was led by Stefan Kohler (IP / Life Sciences – pictured) and Christoph Niederer (Tax).